Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating ...

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

Explore the world of weight loss drugs. Find out how GLP-1-based drugs can lead to significant weight loss, but also bone and ...

Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health care ...

Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...

Around the holidays – when many people are baking cookies for Santa, enjoying cocktail parties or having festive family feasts – some adults who use popular medications for diabetes or weight loss ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Jim Gaffigan opened up about shedding 50 pounds on The View, sharing a moment with co-host Whoopi Goldberg as they discussed ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.